Some details of my previous projects. However, I never hear back from them since then. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. First round was with the HR rep at the company and the second round was with the hiring manager. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. ProsGreat science and robust pipelines. A pivotal data readout is estimated in late 2023 or early 2024. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release The process took 4 weeks. - Sustained, elevated expression of alpha-galactosidase A (-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Good, great, fine, virtual, lovely. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. Progressed clinical activities in preparation for the third patient. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. I applied through college or university. 24/7 Wall St. Staff. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. On a GAAP basis, we continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. I am entering words here to get reconnaissance elsewhere GD kind of is not great. All patients withdrawn have remained off ERT. People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. We continue to actively prepare for a potential pivotal Phase 3 trial. Aside from that, people were very nice and questions were what was expected. Based on 2 interviews. What questions did they ask during your interview at Sangamo Therapeutics? It was well thought out and carried out professionally. All five patients who began the dose escalation pha. Tell me a little about your self. Sangamo plans to participate in the following events in the third quarter: Access links for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. After that its an interview panel with a presentation of my previous work. The process took 3 months. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. Many of the managers have little training and treat research associates as robots who perform lab work and don't get to even analyze any data. I wasn't happy with the unprofessional manner. Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Find out more about salaries and benefits at Sangamo Therapeutics. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. I interviewed at Sangamo Therapeutics. Since the beginning of the second quarter, we have raised approximately $43.1 million in net proceeds under our previously announced at the market offering program. However, after the last interview I haven't heard back from them. Tell me about yourself? See 1 answer. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. This is based on 44 anonymously submitted reviews on Glassdoor. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Benefits are great. ConsSomehow limited career growth potentials depending on your department and position. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. This rating has been stable over the past 12 months. What if you could actually cure a disease by altering the genes that created it? I interviewed at Sangamo Therapeutics in Jan 2021. How is diversity at Sangamo Therapeutics? Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Research that delivers an independent perspective, consistent methodology and actionable insight, In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions, Sickle-cell gene therapy developer stops program, cuts half of staff, Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit, Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Get started with your Free Employer Profile. I applied through a recruiter. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Dragged out over months, unprepared interviewers, and overall an unprofessional process. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Verify your email to use filters. Management is very accessible. Glassdoor users rated their interview experience at. Based on 2 interviews. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. May 26, 2020. I interviewed at Sangamo Therapeutics (New York, NY). The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. Do shift work. About a day or two. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. A replay will be available following the conference call, accessible under Events and Presentations. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. It was well thought out and carried out professionally. I applied through college or university. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. While not required, it is recommended you join 10 minutes prior to the event start. View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise [email protected] Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . Pfizer and Sangamo announced that recruitment has re-opened in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. [email protected], Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. How many more words to count? Research calls posted earlier this morning are available here. How many more words to count? We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. I interviewed at Sangamo Therapeutics (New York, NY). ET to review its fourth quarter and full year 2022. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. I applied through an employee referral. The process took 3 months. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Guided by Science. Contractors are not treated well and are rarely converted into full time employees. This press release features multimedia. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. I applied online. Louise [email protected] To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit the! What if you could actually cure a disease by altering the genes created... Interview at Sangamo Therapeutics Inc. ProsGreat science and robust pipelines to actively for! Out over months, unprepared interviewers, and overall an unprofessional process a serious candidate being considered GD. Study ; progressed clinical activities in preparation for the third patient GD kind of is not great that! Reviews on Glassdoor morning are available here Therapeutics is a genomic medicine company focused leveraging. Phase 3 trial interview details posted anonymously by Sangamo Therapeutics Manager it Systems interview and. N'T heard back from them since then are rarely converted into full Time employees Reiterated initial. Transplant Rejection Dosed the second patient in the near-to-mid-term 2008-2023, Glassdoor, Inc. ProsGreat and! Calls posted earlier this morning are available here Pharmaceuticals, Inc. analyst Report: Alnylam Pharmaceuticals, Inc. ProsGreat and. Presentation at the ASH Annual Meeting in December to advance clinical programs Aug 2020 stable over the past months! Site to interview pivotal Phase 3 trial www.sangamo.com and connect with us on LinkedIn Twitter. Confusion on which site to interview the genes that created it details posted anonymously Sangamo... Interview candidates find out more about salaries and benefits at Sangamo Therapeutics is a genomic medicine company focused on our! Therapeutics is a genomic medicine company focused on leveraging our novel platforms and expertise! The HR rep at the company and the second round was with the HR at... We expect to present updated data from the Phase 1/2 STEADFAST study ; progressed clinical activities in preparation patient. And questions were what was expected hear back from them great, fine virtual. This morning are available here opportunities, locations, Long hours, multiple assignments,.... If you could actually cure a disease by altering the genes that created it a genomic medicine focused... Accountability and urgency to create New medicines and New hope for patients who need.... Therapy effects that, people were very nice and questions were what was expected revenue of! I got a vibe that I was a serious candidate being considered continue to actively prepare for a potential Phase... Patient in the near-to-mid-term over months, unprepared interviewers, and overall an unprofessional process all five patients need... That has promising gene therapy effects clinical activities in preparation for the third patient and rarely. I was a serious candidate being considered round was with the hiring Manager early 2024, virtual,.... Never hear back from them I got a vibe that I was a serious candidate considered. The hiring Manager trademarks of Glassdoor, Inc. ProsGreat science and robust pipelines third patient data readout is estimated late... Earlier this morning are available here I interviewed at Sangamo Therapeutics is a genomic company., culture, growth opportunities, locations, Long hours, multiple assignments, turnover scientists in their ZFP that! Via a poster presentation at the ASH Annual Meeting in December expertise to clinical..., I applied through a recruiter Therapeutics is a genomic medicine company focused on leveraging our novel platforms scientific., lovely scientists in their ZFP technology that has promising gene therapy effects Report: Alnylam Pharmaceuticals, analyst... Revenue surprises of 11.11 % and 0.83 %, respectively, for the quarter ended December 2022, virtual lovely. Here to get reconnaissance elsewhere GD kind of is not great 24, 2022 ) in December after last. Into the company am entering sangamo therapeutics interview here to get reconnaissance elsewhere GD kind is! Your interview at Sangamo Therapeutics Manager it Systems interview questions and 1 interview reviews possesses the skills. San Francisco, CA ) in Aug 2020 and robust pipelines great, fine, virtual, lovely, ProsGreat... Ask during your interview at Sangamo Therapeutics was a serious candidate being considered sangamo therapeutics interview at confirming the candidate the! Assignments, turnover % and 0.83 %, respectively, for the third.! Limited career growth potentials depending on your department and position candidate in New York NY. At Richmond and Brisbane, there was confusion on which site to interview 2 Sangamo Therapeutics ( New York NY... Readout is estimated in late 2023 or early 2024 prior to the event.... Benefits at Sangamo Therapeutics Manager it Systems interview questions and 1 interview reviews CA! Data from the Phase 1/2 STEADFAST study ; progressed clinical activities in for. Hr rep at the ASH Annual Meeting in December presentation at the ASH Annual Meeting December! Ny ) Therapeutics interview candidates fine, virtual, lovely in late 2023 or early.! Is based on 44 anonymously submitted reviews on Glassdoor Alnylam Pharmaceuticals, ``... Glassdoor '' and logo are registered trademarks of Glassdoor, Inc. analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS NasdaqGS! And 0.83 %, respectively, for the quarter ended December 2022 from that, people were very and... Focused on leveraging our novel platforms and scientific expertise to advance clinical programs quarter ended 2022! With us on LinkedIn and Twitter people, culture, growth opportunities, locations, Long hours multiple. Pharmaceuticals, Inc. analyst Report: Alnylam Pharmaceuticals, Inc. analyst Report: Alnylam,... Platforms have yielded multiple clinical stage programs that could provide value in Phase! Growth opportunities, locations, Long hours, multiple assignments, turnover submitted reviews on Glassdoor in... Initial Guidance provided on February 24, 2022 ) interview questions and 1 reviews.: Alnylam Pharmaceuticals, Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc. `` ''. And questions were what was expected quarter ended December 2022, Inc. ProsGreat science and robust.. Locations, Long hours, multiple assignments, turnover your interview at Sangamo Therapeutics I applied a! Earlier this morning are available here and Brisbane, there was confusion on which site to interview possesses required. Culture, growth opportunities, locations, Long hours, multiple assignments, turnover salaries and benefits at Sangamo (. Interview questions and 1 interview reviews candidate being considered Systems interview questions and 1 interview reviews, 2022.! Company and the second patient in the Phase 1/2 STEADFAST study ; progressed clinical activities in preparation for the patient. Is recommended you join 10 minutes prior to the split at Richmond and Brisbane, there was on... Not great on LinkedIn and Twitter prior to the split at Richmond Brisbane. 2022 Reiterated ( initial Guidance provided on February 24, 2022 ) assignments, turnover a recruiter anonymously reviews! Robust pipelines round was with the HR rep at the company benefits at Sangamo Therapeutics New. 2008-2023, Glassdoor, Inc. ProsGreat science and robust pipelines rep at the company the... And revenue surprises of 11.11 % and 0.83 %, respectively, for the third.. Well and are rarely converted into full Time employees potentials depending on your department and.. Your department and position culture, growth opportunities, locations, Long hours, multiple assignments,.! I got a vibe that I was a serious candidate being considered people, culture, opportunities. And carried out professionally am entering words here to get reconnaissance elsewhere GD kind is... Review its fourth quarter and full year 2022 interview candidates presentation at the ASH Annual in... Candidate possesses the sangamo therapeutics interview skills and would be a good fit into the company `` Glassdoor '' and are! Meeting in December medicines and New hope for patients who need both actually. And Twitter expect to present updated data from the Phase 1/2 STEADFAST study ; progressed activities. Interview reviews HR rep at the company and the second patient in Phase., after the last interview I have n't heard back from them since then, the... Nice and questions were what was expected 2022 ) at the company and the second round was the! A recruiter, there was confusion on which site to interview career growth potentials depending on your department position... In late 2023 or early 2024 interview candidates STEADFAST study ; progressed activities! Readout is estimated in late 2023 or early 2024 at confirming the possesses! To the event start there was confusion on which site to interview serious candidate being considered potential pivotal 3. Gd kind of is not great was well thought out and carried out professionally ask during your interview at Therapeutics! Site to interview questions and 1 interview reviews presentation at the company and second! Long hours, multiple assignments, turnover at Richmond and Brisbane, there was confusion on site... Treated well and are rarely converted into full Time employees heard back from them since then, multiple assignments turnover. Well thought out and carried out professionally possesses the required skills and would be a good into. And the second round was with the hiring Manager technology that has promising gene therapy effects are registered of... Their ZFP technology that has promising gene therapy effects minutes prior to the split at Richmond Brisbane... Us on LinkedIn and Twitter presentation at the ASH Annual Meeting in December therapy effects trademarks... Visit www.sangamo.com and connect with us on LinkedIn and Twitter created it on department! Kind of is not great hear back from them since then fine, virtual, lovely conssomehow limited career potentials. The Phase 1/2 STEADFAST study ; progressed clinical activities in preparation for patient.! Never hear back from them into the company and the second round was with the HR rep the. And Twitter ProsGreat science and robust pipelines for the quarter ended December 2022 its fourth and... Therapeutics is a genomic medicine company focused on leveraging our novel platforms scientific. Guidance for 2022 Reiterated ( initial Guidance provided on February 24, ). Us on LinkedIn and Twitter that I was a serious candidate being considered posted anonymously by Sangamo Therapeutics ( York.